Amar Agha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amar Agha has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Diarmuid Smith
7 shared publications- Nigel Glynn
Division of Neuro-endocrinology, Beaumont Hospital and the RCSI Medical School, Dublin, Ireland
7 shared publications - Christopher J. Thompson
Academic Department of Endocrinology, Beaumont Hospital, Dublin, Ireland
5 shared publications Lucy Ann Behan
4 shared publications- Rachel Katherine Crowley
Department of Endocrinology, St Vincents University Hospital, Dublin, Ireland
4 shared publications Bairbre Rogers
3 shared publications
Latest Publications
- Open Access
- 14 September 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-10
The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
Background: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behaviour in GHD hypopituitary patients, pre- and post-growth hormone (GH) replacement. Methods: This study utilizes a physiological flow-based assay to quantify platelet function in whole blood from patient cohorts under arterial shear. Thirteen GH Naïve hypopituitary adults with GHD and thirteen healthy matched controls were studied. Patients were assessed before and after GH treatment. All other pituitary replacements were optimised before the study. In addition to a full endocrine profile, whole blood was labelled and perfused over immobilised von Willibrand factor (vWF). Seven parameters of dynamic platelet-vWF interactions were recorded using digital image microscopy and analysed by customised platelet tracking software. Results: We found a significantly altered profile of platelet-vWF interactions in GHD individuals compared to healthy controls. Specifically, we observed a marked increase in platelets shown to form associations such as tethering, rolling and adherence to immobilized vWF, which were reduced post GH treatment. Speed and distance platelets travelled across vWF was similar between controls and pre-therapy GHD patients, however, this was considerably increased post treatment. This may indicate reduced platelet signaling resulting in less stable adhesion of platelets post GH treatment. Conclusions: Taken together observed differences in platelet behaviour may contribute to an increased risk of thrombosis in GHD which can in part be reversed by GH therapy.
- 14 September 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-10
Open AccessThe modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
Background: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behaviour in GHD hypopituitary patients, pre- and post-growth hormone (GH) replacement. Methods: This study utilizes a physiological flow-based assay to quantify platelet function in whole blood from patient cohorts under arterial shear. Thirteen GH Naïve hypopituitary adults with GHD and thirteen healthy matched controls were studied. Patients were assessed before and after GH treatment. All other pituitary replacements were optimised before the study. In addition to a full endocrine profile, whole blood was labelled and perfused over immobilised von Willibrand factor (vWF). Seven parameters of dynamic platelet-vWF interactions were recorded using digital image microscopy and analysed by customised platelet tracking software. Results: We found a significantly altered profile of platelet-vWF interactions in GHD individuals compared to healthy controls. Specifically, we observed a marked increase in platelets shown to form associations such as tethering, rolling and adherence to immobilized vWF, which were reduced post GH treatment. Speed and distance platelets travelled across vWF was similar between controls and pre-therapy GHD patients, however, this was considerably increased post treatment. This may indicate reduced platelet signaling resulting in less stable adhesion of platelets post GH treatment. Conclusions: Taken together observed differences in platelet behaviour may contribute to an increased risk of thrombosis in GHD which can in part be reversed by GH therapy.
- 1 April 2019
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 188 (4) , 1201-1206
Hypopituitarism post traumatic brain injury (TBI): review
Post-traumatic hypopituitarism (PTHP) is an important and relatively common complication of TBI (traumatic brain injury). A number of studies have shown that this clinical phenomenon can occur soon after TBI (acute) or later in the chronic phase. Patients with moderate to severe TBI are at a particular risk of developing PTHP. In the acute setting, it is important to monitor patients for hypoadrenalism as this confers a high risk for morbidity and even mortality. The gonadotrophin, growth hormone and TSH deficiencies are better defined in the chronic phase. Untreated PTHP can lead to delayed recovery, impaired rehabilitation and persistent neuropsychiatric symptoms. This review will discuss the frequency and natural history of PTHP and its clinical implications and propose a pathway for investigation and management of this still under-recognised entity.
- 1 April 2019
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 188 (4) , 1201-1206
Hypopituitarism post traumatic brain injury (TBI): review
Post-traumatic hypopituitarism (PTHP) is an important and relatively common complication of TBI (traumatic brain injury). A number of studies have shown that this clinical phenomenon can occur soon after TBI (acute) or later in the chronic phase. Patients with moderate to severe TBI are at a particular risk of developing PTHP. In the acute setting, it is important to monitor patients for hypoadrenalism as this confers a high risk for morbidity and even mortality. The gonadotrophin, growth hormone and TSH deficiencies are better defined in the chronic phase. Untreated PTHP can lead to delayed recovery, impaired rehabilitation and persistent neuropsychiatric symptoms. This review will discuss the frequency and natural history of PTHP and its clinical implications and propose a pathway for investigation and management of this still under-recognised entity.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
The diagnostic utility of late night salivary cortisol (LNSF) and cortisone (LNSE) in Cushing's Syndrome and their relationship to metabolic markers
The diagnosis of Cushing’s Syndrome (CS) requires demonstration of excess circulating cortisol. Measurement of late night salivary cortisol (LNSF) has been advocated as a simple, non-invasive and reliable outpatient diagnostic tool for patients with suspected CS but the usefulness of its metabolite cortisone (LNSE) remains unclear. LNSE levels are approximately six times higher than LNSF in saliva due to the rapid action of 11β-hydroxysteroid dehydrogenase type 2 (11βHSD), and have been shown to have a linear relationship with serum free cortisol. We hypothesised that LNSE concentrations may therefore correlate with degree of metabolic derangement resulting from hypercortisolemia. In this study, we investigated the sensitivity of LNSF and LNSE (measured using liquid chromatography-mass spectrometry, LCMS) as compared to the traditional urine free cortisol (UFC) and overnight dexamethasone suppression test (ONDST) in patients with confirmed CS. We also studied any association between LNSF or LNSE and metabolic parameters affected by cortisol excess including HbA1C, ALT and blood pressure (BP). Eighteen patients (15 female) with confirmed CS attending Beaumont Hospital were included. Sixteen patients had ACTH-dependent CS. Median age was 34 years (range 7 – 65). Both LNSF and LNSE were strongly correlated with UFC (R 0.53, P=0.03 and R 0.69, P=0.01 respectively). Sensitivity of ONDST was 100% (data for 17 patients). UFC was measured in 17 patients – median number of samples 1.5 (range1–6) with a sensitivity of 92%. One patient with confirmed CS had four measurements for UFC, all of which were negative. Median number of LNSF and LNSE samples measured was 3 (range 1–18). LNSF had a sensitivity of 91%, while LNSE had a sensitivity of 84%. Seventeen of 18 LNSF samples were positive in the patient with four negative UFCs. Serial LNSF and LNSE identified four patients with cyclical Cushing’s Disease. Six patients (33%) had diabetes mellitus, 11 (61%) were hypertensive, and 11 (61%) were obese. On multivariate analysis, LNSF was not significantly associated with HbA1C, ALT or BP, while LNSE was negatively associated with HbA1C (P=0.04) but not with BP or ALT. When the ratio of LNSF to LNSE was studied, there was no significant effect on metabolic parameters. Late night salivary cortisol is more sensitive than salivary cortisone as a diagnostic test for CS and may identify cases of cyclical ACTH secretion. We did not identify an association between LNSF and metabolic parameters influenced by hypercortisolemia. The negative association between LNSE and HbA1C requires further elucidation.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
The diagnostic utility of late night salivary cortisol (LNSF) and cortisone (LNSE) in Cushing's Syndrome and their relationship to metabolic markers
The diagnosis of Cushing’s Syndrome (CS) requires demonstration of excess circulating cortisol. Measurement of late night salivary cortisol (LNSF) has been advocated as a simple, non-invasive and reliable outpatient diagnostic tool for patients with suspected CS but the usefulness of its metabolite cortisone (LNSE) remains unclear. LNSE levels are approximately six times higher than LNSF in saliva due to the rapid action of 11β-hydroxysteroid dehydrogenase type 2 (11βHSD), and have been shown to have a linear relationship with serum free cortisol. We hypothesised that LNSE concentrations may therefore correlate with degree of metabolic derangement resulting from hypercortisolemia. In this study, we investigated the sensitivity of LNSF and LNSE (measured using liquid chromatography-mass spectrometry, LCMS) as compared to the traditional urine free cortisol (UFC) and overnight dexamethasone suppression test (ONDST) in patients with confirmed CS. We also studied any association between LNSF or LNSE and metabolic parameters affected by cortisol excess including HbA1C, ALT and blood pressure (BP). Eighteen patients (15 female) with confirmed CS attending Beaumont Hospital were included. Sixteen patients had ACTH-dependent CS. Median age was 34 years (range 7 – 65). Both LNSF and LNSE were strongly correlated with UFC (R 0.53, P=0.03 and R 0.69, P=0.01 respectively). Sensitivity of ONDST was 100% (data for 17 patients). UFC was measured in 17 patients – median number of samples 1.5 (range1–6) with a sensitivity of 92%. One patient with confirmed CS had four measurements for UFC, all of which were negative. Median number of LNSF and LNSE samples measured was 3 (range 1–18). LNSF had a sensitivity of 91%, while LNSE had a sensitivity of 84%. Seventeen of 18 LNSF samples were positive in the patient with four negative UFCs. Serial LNSF and LNSE identified four patients with cyclical Cushing’s Disease. Six patients (33%) had diabetes mellitus, 11 (61%) were hypertensive, and 11 (61%) were obese. On multivariate analysis, LNSF was not significantly associated with HbA1C, ALT or BP, while LNSE was negatively associated with HbA1C (P=0.04) but not with BP or ALT. When the ratio of LNSF to LNSE was studied, there was no significant effect on metabolic parameters. Late night salivary cortisol is more sensitive than salivary cortisone as a diagnostic test for CS and may identify cases of cyclical ACTH secretion. We did not identify an association between LNSF and metabolic parameters influenced by hypercortisolemia. The negative association between LNSE and HbA1C requires further elucidation.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Clinical characteristics and management of 4 patients with chordomas of the skull base attending Beaumont Hospital
Introduction: Chordomas are rare slowly growing locally aggressive neoplasms of the bone arising from embryonic remnants of notochord. These tumours typically occur in the axial skeleton and have a proclivity for the spheno-occipital region of the skull base. Parasellar/clivus chordomas account for one third of all chordomas. Methods: We conducted a retrospective chart review of 4 patients with chordomas of the clivus treated in Beaumont Hospital between 2011 and 2017. Results: Three of the four patients were male. The median age at presentation was 39 years and the median length of follow-up was 36.5 months. All patients presented with headaches, diplopia and cranial nerve palsies. 6th cranial nerve involvement was noted in all cases at the time of the presentation. Magnetic resonance imaging was employed to localise the tumours. 3 of the patients had evidence of local invasion. None of the patients had clinical evidence of tumour metastasis to distant sites. All patients underwent surgery followed by adjuvant high-dose proton radiotherapy. 3 patients had craniotomies, while one patient had EM guided endoscopic trans-nasal tumour excision. There was no post-operative mortality. However 3 of the 4 patients had evidence of post-operative pituitary dysfunction. Recurrence was noted in one patient. Six further surgical excisions were required prior to radiotherapy (time to first recurrence was 22 months). None of the 4 patients returned to their pre-morbid status, as they all have residual cranial nerve palsies. Conclusion: Chordomas are aggressive invasive tumours. A multidisciplinary approach in a neurosurgical centre is necessary in the management of these rare tumours. The best results in the treatment of chordomas are reported when using surgery and adjuvant radiotherapy.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Clinical characteristics and management of 4 patients with chordomas of the skull base attending Beaumont Hospital
Introduction: Chordomas are rare slowly growing locally aggressive neoplasms of the bone arising from embryonic remnants of notochord. These tumours typically occur in the axial skeleton and have a proclivity for the spheno-occipital region of the skull base. Parasellar/clivus chordomas account for one third of all chordomas. Methods: We conducted a retrospective chart review of 4 patients with chordomas of the clivus treated in Beaumont Hospital between 2011 and 2017. Results: Three of the four patients were male. The median age at presentation was 39 years and the median length of follow-up was 36.5 months. All patients presented with headaches, diplopia and cranial nerve palsies. 6th cranial nerve involvement was noted in all cases at the time of the presentation. Magnetic resonance imaging was employed to localise the tumours. 3 of the patients had evidence of local invasion. None of the patients had clinical evidence of tumour metastasis to distant sites. All patients underwent surgery followed by adjuvant high-dose proton radiotherapy. 3 patients had craniotomies, while one patient had EM guided endoscopic trans-nasal tumour excision. There was no post-operative mortality. However 3 of the 4 patients had evidence of post-operative pituitary dysfunction. Recurrence was noted in one patient. Six further surgical excisions were required prior to radiotherapy (time to first recurrence was 22 months). None of the 4 patients returned to their pre-morbid status, as they all have residual cranial nerve palsies. Conclusion: Chordomas are aggressive invasive tumours. A multidisciplinary approach in a neurosurgical centre is necessary in the management of these rare tumours. The best results in the treatment of chordomas are reported when using surgery and adjuvant radiotherapy.
- 16 December 2016
- Vol. 129 (1447) , 86-90
Delayed recovery of adipsic diabetes insipidus (ADI) caused by elective clipping of anterior communicating artery and left middle cerebral artery aneurysms.
Adipsic diabetes insipidus (ADI) is an extremely rare complication following microsurgical clipping of anterior communicating artery aneurysm (ACoA) and left middle cerebral artery (MCA) aneurysm. It poses a significant challenge to manage due to an absent thirst response and the co-existence of cognitive impairment in our patient. Recovery from adipsic DI has hitherto been reported only once. A 52-year-old man with previous history of clipping of left posterior communicating artery aneurysm 20 years prior underwent microsurgical clipping of ACoA and left MCA aneurysms without any intraoperative complications. Shortly after surgery, he developed clear features of ADI with adipsic severe hypernatraemia and hypotonic polyuria, which was associated with cognitive impairment that was confirmed with biochemical investigations and cognitive assessments. He was treated with DDAVP along with a strict intake of oral fluids at scheduled times to maintain eunatremia. Repeat assessment at six months showed recovery of thirst and a normal water deprivation test. Management of ADI with cognitive impairment is complex and requires a multidisciplinary approach. Recovery from ADI is very rare, and this is only the second report of recovery in this particular clinical setting.
- 16 December 2016
- Vol. 129 (1447) , 86-90
Delayed recovery of adipsic diabetes insipidus (ADI) caused by elective clipping of anterior communicating artery and left middle cerebral artery aneurysms.
Adipsic diabetes insipidus (ADI) is an extremely rare complication following microsurgical clipping of anterior communicating artery aneurysm (ACoA) and left middle cerebral artery (MCA) aneurysm. It poses a significant challenge to manage due to an absent thirst response and the co-existence of cognitive impairment in our patient. Recovery from adipsic DI has hitherto been reported only once. A 52-year-old man with previous history of clipping of left posterior communicating artery aneurysm 20 years prior underwent microsurgical clipping of ACoA and left MCA aneurysms without any intraoperative complications. Shortly after surgery, he developed clear features of ADI with adipsic severe hypernatraemia and hypotonic polyuria, which was associated with cognitive impairment that was confirmed with biochemical investigations and cognitive assessments. He was treated with DDAVP along with a strict intake of oral fluids at scheduled times to maintain eunatremia. Repeat assessment at six months showed recovery of thirst and a normal water deprivation test. Management of ADI with cognitive impairment is complex and requires a multidisciplinary approach. Recovery from ADI is very rare, and this is only the second report of recovery in this particular clinical setting.
- 3 November 2016
- Published by Wiley in Clinical Endocrinology
- Vol. 86 (5) , 747-754
The effect of growth hormone replacement on the thyroid axis in patients with hypopituitarism: in vivo and ex vivo studies
Summary: Objective: Alterations in the hypothalamic–pituitary–thyroid axis have been reported following growth hormone (GH) replacement. The aim was to examine the relationship between changes in serum concentration of thyroid hormones and deiodinase activity in subcutaneous adipose tissue, before and after GH replacement.Design: A prospective, observational study of patients receiving GH replacement as part of routine clinical care.Patients: Twenty adult hypopituitary men.Measurements: Serum TSH, thyroid hormones – free and total thyroxine (T4) and triiodothyronine (T3) and reverse T3, thyroglobulin and thyroid‐binding globulin (TBG) levels were measured before and after GH substitution. Changes in serum hormone levels were compared to the activity of deiodinase isoenzymes (DIO1, DIO2 and DIO3) in subcutaneous adipose tissue.Results: The mean daily dose of growth hormone (GH) was 0·34 ± 0·11 mg (range 0·15–0·5 mg). Following GH replacement, mean free T4 levels declined (−1·09 ± 1·99 pmol/l, P = 0·02). Reverse T3 levels also fell (−3·44 ± 1·42 ng/dl, P = 0·03) and free T3 levels increased significantly (+0·34 ± 0·15 pmol/l, P = 0·03). In subcutaneous fat, DIO2 enzyme activity declined; DIO1 and DIO3 activities remained unchanged following GH substitution. Serum TSH, thyroglobulin and TBG levels were unaltered by GH therapy.Conclusions: In vitro analysis of subcutaneous adipose tissue from hypopituitary human subjects demonstrates that GH replacement is associated with significant changes in deiodinase isoenzyme activity. However, the observed variation in enzyme activity does not explain the changes in the circulating concentration of thyroid hormones induced by GH replacement. It is possible that deiodinase isoenzymes are differentially regulated by GH in other tissues including liver and muscle.
- 3 November 2016
- Published by Wiley in Clinical Endocrinology
- Vol. 86 (5) , 747-754
The effect of growth hormone replacement on the thyroid axis in patients with hypopituitarism: in vivo and ex vivo studies
Summary: Objective: Alterations in the hypothalamic–pituitary–thyroid axis have been reported following growth hormone (GH) replacement. The aim was to examine the relationship between changes in serum concentration of thyroid hormones and deiodinase activity in subcutaneous adipose tissue, before and after GH replacement.Design: A prospective, observational study of patients receiving GH replacement as part of routine clinical care.Patients: Twenty adult hypopituitary men.Measurements: Serum TSH, thyroid hormones – free and total thyroxine (T4) and triiodothyronine (T3) and reverse T3, thyroglobulin and thyroid‐binding globulin (TBG) levels were measured before and after GH substitution. Changes in serum hormone levels were compared to the activity of deiodinase isoenzymes (DIO1, DIO2 and DIO3) in subcutaneous adipose tissue.Results: The mean daily dose of growth hormone (GH) was 0·34 ± 0·11 mg (range 0·15–0·5 mg). Following GH replacement, mean free T4 levels declined (−1·09 ± 1·99 pmol/l, P = 0·02). Reverse T3 levels also fell (−3·44 ± 1·42 ng/dl, P = 0·03) and free T3 levels increased significantly (+0·34 ± 0·15 pmol/l, P = 0·03). In subcutaneous fat, DIO2 enzyme activity declined; DIO1 and DIO3 activities remained unchanged following GH substitution. Serum TSH, thyroglobulin and TBG levels were unaltered by GH therapy.Conclusions: In vitro analysis of subcutaneous adipose tissue from hypopituitary human subjects demonstrates that GH replacement is associated with significant changes in deiodinase isoenzyme activity. However, the observed variation in enzyme activity does not explain the changes in the circulating concentration of thyroid hormones induced by GH replacement. It is possible that deiodinase isoenzymes are differentially regulated by GH in other tissues including liver and muscle.
- Open Access
- 2 August 2016
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 16 (1) , 1-7
Utility of repeat cytological assessment of thyroid nodules initially classified as benign: clinical insights from multidisciplinary care in an Irish tertiary referral centre
Fine needle aspiration biopsy (FNAB) is the tool of choice for evaluating thyroid nodules with the majority classified as benign following initial assessment. However, concern remains about false negative results and some guidelines have recommended routine repeat aspirates. We aimed to assess the utility of routine repeat FNAB for nodules classified as benign on initial biopsy and to examine the impact of establishing a multidisciplinary team for the care of these patients. We performed a retrospective review of 400 consecutive patients (413 nodules) who underwent FNAB of a thyroid nodule at our hospital between July 2008 and July 2011. Data recorded included demographic, clinical, histological and radiological variables. Three hundred and fifty seven patients (89 %) were female. Median follow-up was 5.5 years. Two hundred and fifty eight (63 %) nodules were diagnosed as benign. The rate of routine repeat biopsy increased significantly over the time course of the study (p for trend = 0.012). Nine Thy 2 nodules were classified differently on the basis of routine repeat biopsy; one patient was classified as malignant on repeat biopsy and was diagnosed with papillary thyroid carcinoma. Eight were classified as a follicular lesions on repeat biopsy—six diagnosed as benign following lobectomy; two declined lobectomy and were followed radiologically with no nodule size increase. The false negative rate of an initial benign cytology result, from a thyroid nodule aspirate, is low. In the setting of an experienced multidisciplinary thyroid team, routine repeat aspiration is not justified.
- 2 August 2016
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 16 (1) , 1-7
Open AccessUtility of repeat cytological assessment of thyroid nodules initially classified as benign: clinical insights from multidisciplinary care in an Irish tertiary referral centre
Fine needle aspiration biopsy (FNAB) is the tool of choice for evaluating thyroid nodules with the majority classified as benign following initial assessment. However, concern remains about false negative results and some guidelines have recommended routine repeat aspirates. We aimed to assess the utility of routine repeat FNAB for nodules classified as benign on initial biopsy and to examine the impact of establishing a multidisciplinary team for the care of these patients. We performed a retrospective review of 400 consecutive patients (413 nodules) who underwent FNAB of a thyroid nodule at our hospital between July 2008 and July 2011. Data recorded included demographic, clinical, histological and radiological variables. Three hundred and fifty seven patients (89 %) were female. Median follow-up was 5.5 years. Two hundred and fifty eight (63 %) nodules were diagnosed as benign. The rate of routine repeat biopsy increased significantly over the time course of the study (p for trend = 0.012). Nine Thy 2 nodules were classified differently on the basis of routine repeat biopsy; one patient was classified as malignant on repeat biopsy and was diagnosed with papillary thyroid carcinoma. Eight were classified as a follicular lesions on repeat biopsy—six diagnosed as benign following lobectomy; two declined lobectomy and were followed radiologically with no nodule size increase. The false negative rate of an initial benign cytology result, from a thyroid nodule aspirate, is low. In the setting of an experienced multidisciplinary thyroid team, routine repeat aspiration is not justified.
- Open Access
- 17 June 2016
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 16 (1) , 36
How should we interrogate the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism?
Hypopituitarism is deficiency of one or more pituitary hormones, of which adrenocorticotrophic hormone (ACTH) deficiency is the most serious and potentially life-threatening. It may occur in isolation or, more commonly as part of more widespread pituitary failure. Diagnosis requires demonstration of subnormal cortisol rise in response to stimulation with hypoglycemia, glucagon, ACTH(1-24) or in the setting of acute illness. The choice of diagnostic test should be individualised for the patient and clinical scenario. A random cortisol and ACTH level may be adequate in making a diagnosis in an acutely ill patient with a suspected adrenal crisis e.g. pituitary apoplexy. Often however, dynamic assessment of cortisol reserve is needed. The cortisol response is both stimulus and assay- dependent and normative values should be derived locally. Results must be interpreted within clinical context and with understanding of potential pitfalls of the test used.
- 17 June 2016
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 16 (1) , 36
Open AccessHow should we interrogate the hypothalamic-pituitary-adrenal axis in patients with suspected hypopituitarism?
Hypopituitarism is deficiency of one or more pituitary hormones, of which adrenocorticotrophic hormone (ACTH) deficiency is the most serious and potentially life-threatening. It may occur in isolation or, more commonly as part of more widespread pituitary failure. Diagnosis requires demonstration of subnormal cortisol rise in response to stimulation with hypoglycemia, glucagon, ACTH(1-24) or in the setting of acute illness. The choice of diagnostic test should be individualised for the patient and clinical scenario. A random cortisol and ACTH level may be adequate in making a diagnosis in an acutely ill patient with a suspected adrenal crisis e.g. pituitary apoplexy. Often however, dynamic assessment of cortisol reserve is needed. The cortisol response is both stimulus and assay- dependent and normative values should be derived locally. Results must be interpreted within clinical context and with understanding of potential pitfalls of the test used.
- Open Access
- 1 January 2016
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 2 (2) , e155-e160
Variable Thyroid-Stimulating Hormone Dynamics in ‘Silent’ Thyrotroph Adenomas
- 1 January 2016
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 2 (2) , e155-e160
Open AccessVariable Thyroid-Stimulating Hormone Dynamics in ‘Silent’ Thyrotroph Adenomas
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
The founder R304*AIPmutation is prevalent in Irish acromegaly and gigantism patients as well as in the general population of Ireland
Background: A founder mutated AIP allele, R304* was previously identified in several Irish familial isolated pituitary adenoma (FIPA) pedigrees from a small region within Mid Ulster, Northern Ireland, but the allele’s general population impact remains unknown. Aims: To estimate R304* prevalence in the general population and pituitary adenoma (PA) patients and to calculate the allele’s time to most recent common ancestor (tMRCA). Methods: We tested for AIP mutations 116 somatotrophinoma patients from the Belfast and Dublin endocrine tertiary referral centres and studied additional R304*-positive pedigrees from our international FIPA database (five Irish/five non-Irish). We genotyped three population samples from Mid Ulster (n=936), Greater Belfast (n=1000) and Republic of Ireland (ROI, n=2094). Based on AIP-centred microsatellite haplotypes, we estimated through coalescent-based simulation the R304* allele’s tMRCA and current number of allele carriers. Results: R304* was very frequent in somatotrophinoma patients (12.6%/6.8% in Belfast/Dublin). General population prevalence estimates were 6/936 (95% CI: 0.0023–0.013; Mid Ulster), 1/1000 (95% CI: 0.000025–0.0055; Greater Belfast) and 0/2094 (95% CI: 0–0·0014; ROI). All 18 Irish pedigrees (two identified through population screening) shared a recent common ancestor, while the non-Irish pedigrees were independent from each other and from the Irish founder. The Irish pedigrees’ median tMRCA was 2550 years (95% CI: 1275–5000). Forward simulation predicted 144 allele carriers/generation (95% CI: 30–1725). Conclusions: R304* has a clinically-relevant prevalence in Ireland, especially in Mid Ulster, due to an approximately 2500-year old founder ancestor. While 40 affected carriers have already been identified, we estimated through forward simulation that 86 PA cases are currently alive (95% CI: 18–1035). Although R304* population screening cannot be currently advocated, our data strongly support the testing of Irish-origin young-onset somatotrophinoma patients. Our study generated increased disease awareness locally, possibly leading to early diagnosis of these typically aggressive AIP-related PAs, crucial to their effective management.
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
The founder R304*AIPmutation is prevalent in Irish acromegaly and gigantism patients as well as in the general population of Ireland
Background: A founder mutated AIP allele, R304* was previously identified in several Irish familial isolated pituitary adenoma (FIPA) pedigrees from a small region within Mid Ulster, Northern Ireland, but the allele’s general population impact remains unknown. Aims: To estimate R304* prevalence in the general population and pituitary adenoma (PA) patients and to calculate the allele’s time to most recent common ancestor (tMRCA). Methods: We tested for AIP mutations 116 somatotrophinoma patients from the Belfast and Dublin endocrine tertiary referral centres and studied additional R304*-positive pedigrees from our international FIPA database (five Irish/five non-Irish). We genotyped three population samples from Mid Ulster (n=936), Greater Belfast (n=1000) and Republic of Ireland (ROI, n=2094). Based on AIP-centred microsatellite haplotypes, we estimated through coalescent-based simulation the R304* allele’s tMRCA and current number of allele carriers. Results: R304* was very frequent in somatotrophinoma patients (12.6%/6.8% in Belfast/Dublin). General population prevalence estimates were 6/936 (95% CI: 0.0023–0.013; Mid Ulster), 1/1000 (95% CI: 0.000025–0.0055; Greater Belfast) and 0/2094 (95% CI: 0–0·0014; ROI). All 18 Irish pedigrees (two identified through population screening) shared a recent common ancestor, while the non-Irish pedigrees were independent from each other and from the Irish founder. The Irish pedigrees’ median tMRCA was 2550 years (95% CI: 1275–5000). Forward simulation predicted 144 allele carriers/generation (95% CI: 30–1725). Conclusions: R304* has a clinically-relevant prevalence in Ireland, especially in Mid Ulster, due to an approximately 2500-year old founder ancestor. While 40 affected carriers have already been identified, we estimated through forward simulation that 86 PA cases are currently alive (95% CI: 18–1035). Although R304* population screening cannot be currently advocated, our data strongly support the testing of Irish-origin young-onset somatotrophinoma patients. Our study generated increased disease awareness locally, possibly leading to early diagnosis of these typically aggressive AIP-related PAs, crucial to their effective management.